There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Replimune Group Inc (REPL), Avenue Therapeutics Inc (ATXI) and Forty Seven Inc (FTSV) with bullish sentiments.
Replimune Group Inc (REPL)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Replimune Group Inc, with a price target of $26. The company’s shares closed last Monday at $10.05, close to its 52-week low of $8.88.
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -10.8% and a 26.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Replimune Group Inc with a $26.67 average price target, implying a 157.9% upside from current levels. In a report released yesterday, Chardan Capital also reiterated a Buy rating on the stock with a $28 price target.
See today’s analyst top recommended stocks >>
Avenue Therapeutics Inc (ATXI)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Avenue Therapeutics Inc today and set a price target of $12. The company’s shares closed last Monday at $5.91.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 5.6% and a 35.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
Avenue Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $12.
Forty Seven Inc (FTSV)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Forty Seven Inc, with a price target of $21. The company’s shares closed last Monday at $6.66, close to its 52-week low of $6.21.
Ramakanth said:
“We maintain our Buy rating on FTSV and our 12-month price target of $21.00 per share. We derive our price target based on a risk-based NPV (rNPV) analysis of projected 5F9 revenues through 2030 assuming a 12% discount rate and a 3% terminal growth rate. We derive rNPV of $1.1B for 5F9 and add in pro forma cash of $180M to arrive at a 12-month price target of $21.17 per share, which we round to $21.00. (1) clinical; (2) partnership; (3) financial; and (4) intellectual property.”
According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -12.5% and a 27.2% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.
Currently, the analyst consensus on Forty Seven Inc is a Strong Buy with an average price target of $23, representing a 193.4% upside. In a report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $20 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
